Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of Its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
18 févr. 2022 17h25 HE
|
Ocugen
MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and...
Ocugen, Inc. Signs Letter of Intent to Acquire Vaccine Manufacturing, R&D Hub in Ontario, Canada
27 janv. 2022 09h25 HE
|
Ocugen
Dormant Vaccine Manufacturing site currently owned by an affiliate of Liminal BioSciences intended to bring new capabilities to Ocugen’s medicine portfolio of Canadian and U.S. companiesCOVAXIN™...
COVAXIN™ (BBV152) Booster Shown to Neutralize Both Omicron and Delta Variants of SARS-CoV-2
12 janv. 2022 06h43 HE
|
Ocugen
Booster dose of candidate vaccine, COVAXIN™ (BBV152), generated robust neutralizing antibody responses against both Omicron (B.1.529) and Delta (B.1.617.2) using a live virus neutralization assay100%...
Ocugen, Inc. to Present at Upcoming H.C. Wainwright Bioconnect Conference
06 janv. 2022 18h03 HE
|
Ocugen
MALVERN, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
New Data Suggest COVAXIN™ (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination
15 déc. 2021 06h46 HE
|
Ocugen
Level of vaccine-induced spike and nucleoprotein antibodies titers demonstrated to be comparable to that following natural infectionImmune memory against conserved nucleoprotein may provide an added...
Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
26 nov. 2021 07h01 HE
|
Ocugen
MALVERN, Pa., Nov. 26, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines,...
Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN™ (BBV152) for Children Ages 2-18 Years
05 nov. 2021 06h38 HE
|
Ocugen
COVAXIN™ (BBV152) was recently awarded Emergency Use Listing by the World Health OrganizationPediatric EUA submission based on immuno-bridging clinical trial in children, ages 2-18, demonstrating...
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
27 oct. 2021 06h35 HE
|
Ocugen
MALVERN, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines,...
Ocugen, Inc. Announces Initiation of Rolling Submission to Health Canada for COVAXIN™
15 juil. 2021 07h34 HE
|
Ocugen
MALVERN, Pa., July 15, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing and commercializing gene therapies to cure blindness...
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease
02 juil. 2021 17h42 HE
|
Ocugen
Efficacy analysis demonstrates COVAXIN™ to be 93.4% protective against severe symptomatic COVID-19Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variantAdverse...